Bellerophon Therapeutics (NASDAQ:BLPH) Now Covered by StockNews.com

by · The Cerbat Gem

StockNews.com began coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH – Free Report) in a research note released on Thursday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Bellerophon Therapeutics Stock Down 25.5 %

BLPH stock opened at $0.01 on Thursday. The business has a 50 day moving average of $0.03 and a 200 day moving average of $0.04. The firm has a market cap of $146,796.00, a PE ratio of -0.01 and a beta of 0.74. Bellerophon Therapeutics has a twelve month low of $0.01 and a twelve month high of $0.02.

Bellerophon Therapeutics Dividend Announcement

The company also recently disclosed a dividend, which was paid on Wednesday, December 18th. Shareholders of record on Friday, December 20th were paid a dividend of $0.019 per share. The ex-dividend date was Thursday, December 19th. This represents a yield of 117.8%.

About Bellerophon Therapeutics

(Get Free Report)

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.

Featured Stories